Hui Zhuang, Professor

Contact Information

zhuangbmu@126.com

Personal profile

Academician of the Chinese Academy of Engineering (CAE), a member of the WHO Advisory Committee on Viral Hepatitis, a member of the WHO Western Pacific Region Expert Committee on Hepatitis B Immunization, and a member of the WHO Western Pacific Region Commission for the Certification of Poliomyelitis Eradication.

He currently serves as a member of the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP) and Honorary Lifetime Director of the Chinese Society of Hepatology, Chinese Medical Association.

Our research mainly focuses on viral hepatitis. He was the first to report and confirm, through immunoelectron microscopy and gene sequencing, the presence of both epidemic and sporadic hepatitis E in China. He established the first laboratory diagnostic techniques and rhesus monkey animal model for hepatitis E in China, and successfully developed the Hepatitis E Virus IgG ELISA Kit and the Hepatitis B Virus Surface Antigen Colloidal Gold Strip, both of which received new drug certificates with protection periods of 2 years and 8 years, respectively.

He was the first to confirm, through epidemiology and serology, the prevalence of hepatitis C among paid plasma donors in China, which was linked to cross-contamination during plasma collection. The subsequent implementation of preventive measures effectively controlled the epidemic. He also firstly confirmed, through epidemiology, molecular biology, and animal infection experiments, the existence of hepatitis G virus infection in China.

In collaboration with relevant institutions in Beijing, he proposed the optimal immunization strategy for neonatal hepatitis B vaccination and developed diagnostic kits for hepatitis A and hepatitis D, generating significant economic and social benefits.

He has published more than 800 papers, edited 4 monographs in Chinese, contributed to 5 English monographs and 32 Chinese monographs, and translated 1 monograph.

He has received three Second-Class National Science and Technology Progress Awards, one U.S. patent, five Chinese patents, and three new drug certificates, as well as multiple First- and Second-Class Science and Technology Progress Awards from the Ministry of Health, the Ministry of Education, and Beijing Municipality.

In 2020, the International Committee on Systematics of Prokaryotes named a newly discovered Mobilicoccus species Mobilicoccus zhuangii in his honor.

In 2024, he received the Okuda-Omata Distinguished Achievement Award from the Asian Pacific Association for the Study of the Liver (APASL).

In 2025, he was awarded the Ho Ying Dong Award for Outstanding Chinese Physicians Worldwide.